RECEFOTCHealthcare · Biotechnology

Recce Pharmaceuticals Ltd

$0.22+0.00%(+$0.00)

TickerSpark Score

41/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RECEF research report →

52-Week Range0% of range

Low $0.22

Current $0.22

High $0.60

Companywww.recce.com.au

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S.

CEO: James Hamilton-Bray Graham
IPO: 2022
HQ: Sydney, NSW, AU

Price Chart

-63.33% · this period

Valuation

Market Cap: $80.36M
P/E: -4.83
P/S: 259.61
P/B: -7.84
EV/EBITDA: -5.82
Div Yield: 0.00%

Profitability

Gross Margin: -277.34%
Op Margin: -3942.32%
Net Margin: -5378.06%
ROE: 279.21%
ROIC: 290.72%

Growth & Income

Revenue: $7.51M · 9.62%
Net Income: $-21,428,089 · -21.33%
EPS: $-0.09 · 9.33%
Op Income: $-22,880,440
FCF YoY: -55.65%

Performance & Tape

52W High: $0.60
52W Low: $0.22
50D MA: $0.22
200D MA: $0.22
Beta: 0.35
Avg Volume: 127.203

Get TickerSpark's AI analysis on RECEF

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime